Bayer Basic EPS 2010-2025 | BAYRY

Bayer annual/quarterly basic eps history and growth rate from 2010 to 2025. Basic eps can be defined as a company's net earnings or losses attributable to common shareholders per basic share basis.
  • Bayer basic eps for the quarter ending June 30, 2025 was $-0.06, a 88.97% decline year-over-year.
  • Bayer basic eps for the twelve months ending June 30, 2025 was $-0.45, a 46.8% decline year-over-year.
  • Bayer annual basic eps for 2024 was $-0.001B, a 13.1% decline from 2023.
  • Bayer annual basic eps for 2023 was $-0.001B, a 172.75% decline from 2022.
  • Bayer annual basic eps for 2022 was $0.001B, a 268.21% increase from 2021.
Bayer Annual Basic EPS
2024 $-0.70
2023 $-0.81
2022 $1.11
2021 $0.30
2020 $-3.05
2019 $1.17
2018 $0.53
2017 $2.38
2016 $1.51
2015 $1.38
2014 $1.38
2013 $1.28
2012 $0.95
2011 $1.01
2010 $0.54
2009 $0.61
Bayer Quarterly Basic EPS
2025-06-30 $-0.06
2025-03-31 $0.35
2024-12-31 $0.43
2024-09-30 $-1.17
2024-06-30 $-0.52
2024-03-31 $0.55
2023-12-31 $0.39
2023-09-30 $-1.27
2023-06-30 $-0.52
2023-03-31 $0.60
2022-12-31 $0.11
2022-09-30 $0.14
2022-06-30 $-0.08
2022-03-31 $0.94
2021-12-31 $0.35
2021-09-30 $0.03
2021-06-30 $-0.72
2021-03-31 $0.64
2020-12-31 $0.02
2020-09-30 $-0.82
2020-06-30 $-2.68
2020-03-31 $0.42
2019-12-31 $0.43
2019-09-30 $0.26
2019-06-30 $0.12
2019-03-31 $0.36
2018-12-31 $-1.27
2018-09-30 $0.86
2018-06-30 $0.26
2018-03-31 $0.69
2017-12-31 $0.20
2017-09-30 $1.31
2017-06-30 $0.39
2017-03-31 $0.49
2016-12-31 $0.13
2016-09-30 $0.40
2016-06-30 $0.47
2016-03-31 $0.51
2015-12-31 $0.21
2015-09-30 $0.34
2015-06-30 $0.39
2015-03-31 $0.45
2014-12-31 $0.06
2014-09-30 $0.33
2014-06-30 $0.39
2014-03-31 $0.59
2013-12-31 $0.19
2013-09-30 $0.30
2013-06-30 $0.33
2013-03-31 $0.46
2012-12-31 $0.14
2012-09-30 $0.20
2012-06-30 $0.19
2012-03-31 $0.42
2011-12-31 $0.16
2011-09-30 $0.28
2011-06-30 $0.33
2011-03-31 $0.29
2010-12-31 $-0.08
2010-09-30 $0.11
2010-06-30 $0.20
2010-03-31 $0.28
2009-12-31 $0.07
2009-09-30 $0.11
2009-06-30 $0.23
2009-03-31 $0.18
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $32.695B $50.438B
Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $673.574B 44.07
Johnson & Johnson (JNJ) United States $431.791B 17.93
AbbVie (ABBV) United States $372.037B 19.89
Novartis AG (NVS) Switzerland $268.235B 14.53
Roche Holding AG (RHHBY) Switzerland $260.064B 0.00
Novo Nordisk (NVO) Denmark $254.416B 15.40
Merck (MRK) United States $218.231B 11.44
Pfizer (PFE) United States $147.142B 7.63
Sanofi (SNY) France $126.091B 12.49
Innoviva (INVA) United States $1.270B 12.52